Post-earnings recap
Reported
Wed, Feb 22, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
The earnings report indicates that United Therapeutics faced challenges in meeting earnings expectations, which resulted in a stock decline of 4.51%. The lack of revenue data and guidance may contribute to uncertainty among investors. Overall, the market reacted negatively due to the significant EPS miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.67 | N/A | -35.15% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over the lower-than-expected EPS. They did not provide any updates on future guidance.
Management acknowledged the unexpected EPS decline.
No specific guidance was provided for future performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—